Treatment for Tibial Plateau Fracture

Phase-Based Progress Estimates
University of Utah Orthopaedic Center, Salt Lake City, UT
Tibial Plateau Fracture+4 More
All Sexes
What conditions do you have?

Study Summary

The purpose of this study is to evaluate both genotypic differences and differences in local gene expression in individuals who develop acute traumatic compartment syndrome relative to control patients with at-risk lower extremity fractures who do not develop compartment syndrome.

Eligible Conditions

  • Tibial Plateau Fracture
  • Tibial Shaft Fractures

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: Immediately after the muscle tissue harvest procedure.

Immediately after the muscle tissue harvest procedure.
Myostatin (% increase)

Trial Safety

Safety Progress

1 of 3

Trial Design

0 Treatment Group

80 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: immediately after the muscle tissue harvest procedure.

Trial Background

Justin Haller, Principle Investigator
Principal Investigator
University of Utah
Closest Location: University of Utah Orthopaedic Center · Salt Lake City, UT
Photo of Salt Lake City  1Photo of Salt Lake City  2Photo of Salt Lake City  3
2019First Recorded Clinical Trial
1 TrialsResearching Tibial Plateau Fracture
15 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a patient who is 18 years of age or older
Patients without clinical compartment syndrome undergoing operative intervention within 48 hours of injury for tibial shaft or tibial plateau fractures.
You have a clinical diagnosis of lower leg acute compartment syndrome secondary to tibial shaft or tibial plateau fracture.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.